Bifogade filer
KDventures’ portfolio company SVF Vaccines partners with Touchlight to accelerate SVF-001 toward clinical development
Prenumeration
Kalender
| Est. tid* | ||
| 2026-11-13 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-28 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-13 | N/A | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2026-05-12 | N/A | Årsstämma |
| 2026-04-30 | 08:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-13 | - | Bokslutskommuniké 2025 |
| 2025-11-14 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2025-05-15 | - | Årsstämma |
| 2025-04-30 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-14 | - | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-04-26 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-17 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2022-01-12 | - | Extra Bolagsstämma 2022 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Extra Bolagsstämma 2021 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-16 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2020-06-15 | - | Årsstämma |
| 2020-04-30 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-29 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-28 | - | Årsstämma |
| 2019-05-21 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-08 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-10-31 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-10-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-26 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2016-05-25 | - | Årsstämma |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-21 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-05-06 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
| 2014-12-04 | - | Extra Bolagsstämma 2014 |
| 2014-10-21 | - | Kapitalmarknadsdag 2014 |
| 2014-10-21 | - | Analytiker möte 2014 |
| 2014-10-21 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-15 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2014-05-14 | - | Årsstämma |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-19 | - | Bokslutskommuniké 2013 |
| 2013-11-21 | - | Analytiker möte 2013 |
| 2013-11-21 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-22 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-15 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2013-05-14 | - | Årsstämma |
| 2013-05-10 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-20 | - | Extra Bolagsstämma 2013 |
| 2013-03-20 | - | Bokslutskommuniké 2012 |
| 2013-03-13 | - | 15-7 2013 |
| 2012-11-22 | - | Analytiker möte 2012 |
| 2012-11-22 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-23 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-24 | - | X-dag ordinarie utdelning KDV B 0.00 SEK |
| 2012-05-23 | - | Årsstämma |
| 2012-05-15 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-22 | - | Bokslutskommuniké 2011 |
| 2011-11-29 | - | 15-7 2011 |
| 2011-11-25 | - | Kvartalsrapport 2011-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Finans |
| Industri | Investeringar |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
STOCKHOLM, Sweden, April 9, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a collaboration with Touchlight, a biotechnology company specializing in cell-free DNA manufacturing. The purpose of the collaboration is to accelerate SVF Vaccines’ lead hepatitis B/D immunotherapy program, SVF-001, toward clinical development.
SVF-001 represents a novel approach designed to induce both neutralizing antibody responses and T‑cell responses against key viral targets. Under the collaboration, SVF Vaccines and Touchlight will work together to support the use of Touchlight’s proprietary doggybone DNA™ (dbDNA™) platform, a cell-free DNA technology designed to enable rapid, scalable and high-purity DNA manufacturing. The collaboration is expected to support an efficient path forward as SVF Vaccines advances SVF-001 and prepares the program for the next stage of development.
“The collaboration between our portfolio company SVF Vaccines and Touchlight is a strategically important step in the efforts to expeditiously and efficiently bring the unique hepatitis B/D immunotherapy candidate SVF-001 towards clinical development,” comments Viktor Drvota, CEO of KDventures.
KDventures holds a direct ownership in SVF Vaccines of 33 percent.
Contacts
Viktor Drvota, CEO, KDventures AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@kd-ventures.com
Johan Dighed, General Counsel and Deputy CEO, KDventures AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@kd-ventures.com
About Us
KDventures AB (Nasdaq Stockholm: KDV) is a Nordic investment company specialized in life sciences. The company identifies and invests in innovative pharmaceutical projects and medical technology products originating from leading research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, KDventures creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with significant value growth potential.
For more information, please visit https://www.kd-ventures.com/en.